MARKET

KZIA

KZIA

Kazia Therapeuti
NASDAQ
0.6391
+0.0041
+0.65%
Closed 16:00 12/02 EST
OPEN
0.6101
PREV CLOSE
0.6350
HIGH
0.6400
LOW
0.6101
VOLUME
15.29K
TURNOVER
8.01K
52 WEEK HIGH
10.70
52 WEEK LOW
0.5551
MARKET CAP
8.87M
P/E (TTM)
-0.5027
1D
5D
1M
3M
1Y
5Y
COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication of positive preclinical data for EVT801, a clinical-stage drug candidate currently in a clinical trial for multiple fo...
PR Newswire · 3d ago
Quite a few insiders invested in Kazia Therapeutics Limited (ASX:KZA) last year which is positive news for shareholders
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Simply Wall St. · 5d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/23 13:07
KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentatio...
PR Newswire · 11/09 12:00
Kazia Therapeutics provides cash outlook
Seekingalpha · 11/02 14:44
Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates
Kazia Therapeutics' Q123 cash flow report provided an update on the company's financial position and business progress. While the quarter was dominated by lead asset paxalisib hitting a roadblock (failing to graduate to stage two of the GBM AGILE study), t...
ACCESSWIRE · 11/02 11:10
Why Quanergy Systems Shares Are Trading Sharply Lower; Here Are 28 Stocks Moving Premarket
Benzinga · 10/31 10:36
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 10/28 17:59
More
About KZIA
Kazia Therapeutics Limited is an Australia-based oncology-focused drug development company. The Company is engaged in pharmaceutical research and development. The Company’s drug candidates are designed to treat diseases such as brain cancer, renal cancer, and liver cancer. The Company’s lead programs include paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of VEGFR3. EVT801 is being developed in patients with advanced cancer. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor.

Webull offers kinds of Kazia Therapeutics Ltd (ADR) stock information, including NASDAQ:KZIA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZIA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KZIA stock methods without spending real money on the virtual paper trading platform.